Drugs / Resimmune®
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02990416 | Jan 2017 → Feb 2018 | melanoma | Virogen Biotechnology Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01888081 | Feb 2014 → Dec 2020 | melanoma | Virogen Biotechnology Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02943642 | May 2026 | mycosis fungoides | Virogen Biotechnology Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00611208 | Jan 2008 → Feb 2015 | Sezary syndrome, T-cell leukemia, mycosis fungoides | Virogen Biotechnology Inc. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Resimmune | “A-dmDT390-bisFv(UCHT1) (Resimmune®)” NCT01888081 ↗ |
| Known as | A-dmDT390-bisFv(UCHT1) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00611208 ↗ |
| Known as | LAX-699 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297555 ↗ |
| Action | Deplete | “degree of T cell depletion induced by A-dmDT390-bisFv(UCHT1) fusion protein” NCT00611208 ↗ |
| Action | Inhibit | “Elongation factor 2 inhibitor” CHEMBL4297555 ↗ |
| Modality | Protein / enzyme biologic | “A-dmDT390-bisFv(UCHT1) (Resimmune™), an anti-T cell immunotoxin” NCT01888081 ↗ |
| Route | Intravenous | “into a free flowing IV” NCT00611208 ↗ |
| Target | CD3E | “T-cell surface glycoprotein CD3 epsilon chain binding agent” CHEMBL4297555 ↗ |
| Target | EEF2 | “Elongation factor 2 inhibitor” CHEMBL4297555 ↗ |